Becton, Dickinson And Co. BDX
The next Becton, Dickinson And Co. dividend went ex 17 days ago for 83c and will be paid in 5 days.
The previous Becton, Dickinson And Co. dividend was 83c and it went ex 4 months ago and it was paid 3 months ago.
There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 3.4.
|Summary||Previous dividend||Next dividend|
|Declaration date||27 Apr 2021 (Tue)||27 Jul 2021 (Tue)|
|Ex-div date||08 Jun 2021 (Tue)||08 Sep 2021 (Wed)|
|Pay date||30 Jun 2021 (Wed)||30 Sep 2021 (Thu)|
Enter the number of Becton, Dickinson And Co. shares you hold and we'll calculate your dividend payments:
Sign up for Becton, Dickinson And Co. and we'll email you the dividend information when they declare.
Add Becton, Dickinson And Co. to receive free notifications when they declare their dividends.
Your account is set up to receive Becton, Dickinson And Co. notifications.
|Status||Type||Decl. date||Ex-div date||Pay date||Decl. Currency||Forecast amount||Decl. amount||Accuracy|
|Forecast||Quarterly||28 Jul 2026||08 Sep 2026||30 Sep 2026||USD||Sign up||—|
|Forecast||Quarterly||21 Apr 2026||08 Jun 2026||30 Jun 2026||USD||Sign up||—|
|Forecast||Quarterly||19 Jan 2026||09 Mar 2026||31 Mar 2026||USD||Sign up||—|
|Forecast||Quarterly||18 Nov 2025||10 Dec 2025||01 Jan 2026||USD||Sign up||—|
|Forecast||Quarterly||22 Jul 2025||08 Sep 2025||30 Sep 2025||USD||Sign up||—|
|Forecast||Quarterly||22 Apr 2025||06 Jun 2025||30 Jun 2025||USD||Sign up||—|
|Forecast||Quarterly||20 Jan 2025||07 Mar 2025||31 Mar 2025||USD||Sign up||—|
|Forecast||Quarterly||19 Nov 2024||10 Dec 2024||01 Jan 2025||USD||Sign up||—|
|Forecast||Quarterly||23 Jul 2024||06 Sep 2024||30 Sep 2024||USD||Sign up||—|
|Forecast||Quarterly||23 Apr 2024||06 Jun 2024||28 Jun 2024||USD||Sign up||—|
|Forecast||Quarterly||22 Jan 2024||07 Mar 2024||29 Mar 2024||USD||Sign up||—|
|Forecast||Quarterly||21 Nov 2023||07 Dec 2023||29 Dec 2023||USD||Sign up||—|
|Forecast||Quarterly||25 Jul 2023||07 Sep 2023||29 Sep 2023||USD||Sign up||—|
|Forecast||Quarterly||25 Apr 2023||08 Jun 2023||30 Jun 2023||USD||Sign up||—|
|Forecast||Quarterly||23 Jan 2023||09 Mar 2023||31 Mar 2023||USD||Sign up||—|
|Forecast||Quarterly||22 Nov 2022||08 Dec 2022||30 Dec 2022||USD||Sign up||—|
|Forecast||Quarterly||26 Jul 2022||08 Sep 2022||30 Sep 2022||USD||Sign up||—|
|Forecast||Quarterly||26 Apr 2022||08 Jun 2022||30 Jun 2022||USD||Sign up||—|
|Forecast||Quarterly||24 Jan 2022||09 Mar 2022||31 Mar 2022||USD||Sign up||—|
|Forecast||Quarterly||23 Nov 2021||09 Dec 2021||31 Dec 2021||USD||Sign up||—|
|Declared||Quarterly||27 Jul 2021||08 Sep 2021||30 Sep 2021||USD||83c||83c||😄|
|Paid||Quarterly||27 Apr 2021||08 Jun 2021||30 Jun 2021||USD||83c||83c||😄|
|Paid||Quarterly||25 Jan 2021||09 Mar 2021||31 Mar 2021||USD||83c||83c||😄|
|Paid||Quarterly||24 Nov 2020||09 Dec 2020||31 Dec 2020||USD||81c||83c||😃|
|Paid||Quarterly||27 Jul 2020||08 Sep 2020||30 Sep 2020||USD||79c||79c||😄|
|Paid||Quarterly||28 Apr 2020||08 Jun 2020||30 Jun 2020||USD||79c||79c||😄|
|Paid||Quarterly||27 Jan 2020||09 Mar 2020||31 Mar 2020||USD||79c||79c||😄|
|Paid||Quarterly||25 Nov 2019||09 Dec 2019||31 Dec 2019||USD||79c||79c||😄|
|Paid||Quarterly||22 Jul 2019||06 Sep 2019||30 Sep 2019||USD||77c||77c||😄|
|Paid||Quarterly||29 Apr 2019||06 Jun 2019||28 Jun 2019||USD||—||77c|
|Paid||Quarterly||21 Jan 2019||07 Mar 2019||29 Mar 2019||USD||—||77c|
|Paid||Quarterly||19 Nov 2018||07 Dec 2018||31 Dec 2018||USD||—||77c|
|Paid||Quarterly||24 Jul 2018||06 Sep 2018||28 Sep 2018||USD||—||75c|
|Paid||Quarterly||23 Apr 2018||07 Jun 2018||29 Jun 2018||USD||—||75c|
|Paid||Quarterly||23 Jan 2018||08 Mar 2018||30 Mar 2018||USD||—||75c|
|Paid||Quarterly||20 Nov 2017||07 Dec 2017||29 Dec 2017||USD||—||75c|
|Paid||Quarterly||25 Jul 2017||07 Sep 2017||29 Sep 2017||USD||—||73c|
|Paid||Quarterly||23 May 2017||07 Jun 2017||30 Jun 2017||USD||—||73c|
|Paid||Quarterly||23 Jan 2017||08 Mar 2017||31 Mar 2017||USD||—||73c|
|Paid||Quarterly||21 Nov 2016||07 Dec 2016||30 Dec 2016||USD||—||73c|
|Paid||Quarterly||26 Jul 2016||07 Sep 2016||30 Sep 2016||USD||—||66c|
|Paid||Quarterly||24 May 2016||07 Jun 2016||30 Jun 2016||USD||—||66c|
|Paid||Quarterly||–||08 Mar 2016||31 Mar 2016||USD||—||66c|
|Paid||Quarterly||23 Nov 2015||08 Dec 2015||31 Dec 2015||USD||—||66c|
|Paid||Quarterly||–||04 Sep 2015||30 Sep 2015||USD||—||60c|
|Paid||Quarterly||–||05 Jun 2015||30 Jun 2015||USD||—||60c|
|Paid||Quarterly||27 Jan 2015||06 Mar 2015||31 Mar 2015||USD||—||60c|
|Paid||Quarterly||25 Nov 2014||08 Dec 2014||31 Dec 2014||USD||—||60c|
|Paid||Quarterly||22 Jul 2014||05 Sep 2014||30 Sep 2014||USD||—||54.5c|
|Paid||Quarterly||20 May 2014||05 Jun 2014||30 Jun 2014||USD||—||54.5c|
|Paid||Quarterly||28 Jan 2014||06 Mar 2014||31 Mar 2014||USD||—||54.5c|
|Paid||Quarterly||25 Nov 2013||06 Dec 2013||31 Dec 2013||USD||—||54.5c|
|Paid||Quarterly||23 Jul 2013||05 Sep 2013||30 Sep 2013||USD||—||49.5c|
|Paid||Quarterly||21 May 2013||05 Jun 2013||28 Jun 2013||USD||—||49.5c|
|Paid||Quarterly||29 Jan 2013||06 Mar 2013||29 Mar 2013||USD||—||49.5c|
|Paid||Quarterly||20 Nov 2012||06 Dec 2012||31 Dec 2012||USD||—||49.5c|
|Paid||Quarterly||–||05 Sep 2012||28 Sep 2012||USD||—||45c|
|Paid||Quarterly||–||06 Jun 2012||29 Jun 2012||USD||—||45c|
|2021||Sign Up Required|
|2022||Sign Up Required|
|2023||Sign Up Required|
|2024||Sign Up Required|
|2025||Sign Up Required|
|2026||Sign Up Required|
Becton, Dickinson And Co. Optimized Dividend Chart
About Becton, Dickinson And Co.
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. It provides customer solutions that are focused on managing medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; managing drug delivery; aiding anesthesiology care; managing the diagnosis of infectious diseases and cancers; advancing cellular research and applications, and supporting the management of diabetes. The Company caters to markets, such as healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's subsidiaries include Accuri Cytometers, Inc., BD Norge AS, CareFusion Canada 307 ULC, Vital Signs Hong Kong Limited and Dantor S.A.
The Company's operations outside the United States include Europe; the Middle East and Africa (EMA); Greater Asia, which includes Japan and Asia Pacific; Latin America, which includes Mexico, Central America, the Caribbean and South America, and Canada. BD has manufacturing operations outside the United States in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain and the United Kingdom. It sells its products under various brands, such as BD Hypak, Alaris, Pyxis and Vacutainer, BD Kiestra, BD Max, BD BACTEC, SurePath, Veritor, BD ProbeTec and BD Viper.
The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems.
The diabetes care unit includes various products lines, such as syringes, pen needles and intravenous (IV) sets for the injection or infusion of insulin and other drugs used in the treatment of diabetes. The medication and procedural solutions unit includes various product lines, such as needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products, and surgical and laproscopic instrumentation. The medication management solutions unit includes intravenous medication safety and infusion therapy delivery systems, such as infusion pumps and dedicated disposables; medication compounding workflow systems, and automated medication dispensing and supply management systems. The pharmaceutical systems unit includes prefillable drug delivery systems provided to pharmaceutical companies and sold to end users as drug/device combinations. The businesses served by BD Medical are hospitals and clinics, physicians' office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, and healthcare workers.
BD Life Sciences
The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections (HAIs) and cancers. The BD Life Sciences segment produces research and clinical tools that facilitate the study of cells, the components of cells, and to gain an understanding of normal and disease processes. The BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences. The preanalytical systems unit includes integrated systems for specimen collection, and safety-engineered blood collection products and systems. The diagnostic systems unit includes automated blood culturing and tuberculosis culturing systems, molecular testing systems for infectious diseases and women's health, microorganism identification and drug susceptibility systems, liquid-based cytology systems for cervical cancer screening, rapid diagnostic assays, microbiology laboratory automation, and plated media. The biosciences unit includes fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, human immunodeficiency virus (HIV) and transplantation diagnostic/monitoring reagents and analyzers, and cell culture media supplements for biopharmaceutical manufacturing. The primary businesses served by BD Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians' office practices; academic and government institutions, and pharmaceutical and biotechnology companies.
- Pharmaceuticals & Biotechnology
- United States
- Share Price
- $253.18 (yesterday's closing price)
- Shares in Issue
- 270 million
- Market Cap
- Market Indices
- S&P 500